Abstract

Vericel will release its first-quarter 2026 results on May 7, 2026 Pre-Market; this preview outlines consensus expectations for revenue, margins, and EPS, assesses last quarter’s performance, and synthesizes institutional viewpoints from the past six months through April 30, 2026.

Market Forecast

Consensus for the current quarter points to revenue of 63.64 million US dollars, an estimated year-over-year increase of 18.19%, with an EPS forecast of -0.16 and EBIT of -9.83 million US dollars; the company’s gross profit margin is expected to remain elevated given the prior quarter’s 78.70% level, while net profit margin is likely to be negative on seasonal softness. Vericel’s core portfolio is projected to be led by autologous cartilage repair, with management and analysts highlighting steady procedure growth and strong account retention; NexoBrid and Epicel provide incremental contributions with variability tied to timing of burn-center demand. The most promising segment is autologous cartilage cell therapy, supported by solid demand trends within orthopedic centers; revenue for the segment was 239.51 million US dollars last quarter’s trailing period, and growth expectations are underpinned by procedure adoption and center expansion year over year.

Last Quarter Review

Vericel’s prior quarter delivered revenue of 92.92 million US dollars, a gross profit margin of 78.70%, GAAP net profit attributable to shareholders of 23.24 million US dollars, a net profit margin of 25.01%, and adjusted EPS of 0.45, with year-over-year growth of 23.27% for revenue and 18.42% for adjusted EPS. A key highlight was operating leverage, as EBIT of 22.42 million US dollars exceeded internal and market forecasts alongside robust top-line execution. The main business remained concentrated in autologous cartilage cell therapy at 239.51 million US dollars on a trailing basis, while Epicel contributed 32.07 million US dollars and NexoBrid 4.69 million US dollars, with year-over-year momentum strongest in cartilage therapies.

Current Quarter Outlook

Main business: Autologous cartilage repair

Seasonality typically affects the first quarter due to fewer elective procedures during winter months, which explains the projected negative EPS and EBIT despite a healthy year-over-year revenue increase. The revenue consensus of 63.64 million US dollars implies sustained demand from orthopedic centers, driven by continued adoption and steady surgeon utilization. Margin cadence is expected to compress sequentially from the prior quarter’s peak, but pricing and mix should anchor gross margins well above 70%. Growth drivers include continued penetration in existing accounts, expanding the network of treating centers, and consistent patient identification pathways. The business benefits from a high-value procedure with a favorable reimbursement backdrop, which supports durable price realization. Management’s execution focus, including capacity and supply reliability, remains central to meeting procedure volume growth and limiting cancellations that can pressure quarterly performance.

Most promising business: Autologous cartilage cell therapy scale-up

With trailing-period revenue of 239.51 million US dollars and strong year-over-year increases cited by analysts, the cartilage franchise stands out as the growth engine. The pathway for upside rests on procedure growth, surgeon training throughput, and potential duration-of-therapy efficiencies that could expand capacity without materially increasing fixed costs. Continued account conversions and maturing cohorts of high-volume centers can lift throughput, providing operating leverage over time. Near-term, the segment’s outlook is sensitive to weather-related procedure timing and referral patterns, which can influence quarterly revenue recognition. However, the year-over-year forecast of 18.19% growth for total company revenue suggests sustained momentum, with cartilage therapies doing most of the heavy lifting. Given its scale and high margin profile, this franchise is likely to be the key swing factor for full-year earnings power.

Stock price drivers this quarter

Earnings-day commentary on procedure trends and the spring/summer scheduling pipeline will likely guide sentiment more than the seasonally weak EPS print. Investors will also focus on any updates to full-year guidance, particularly revenue and margin guardrails, to assess whether first-quarter softness is purely seasonal. Finally, burn-care updates—including Epicel demand trends and NexoBrid ordering cadence—could add upside optionality, especially if large institutional or government-related orders come into view. If management reiterates healthy growth in demand indicators and maintains high-70s gross margin targets despite seasonal mix, the market may look through the near-term loss profile. Conversely, any commentary implying slower account growth or procedure delays beyond seasonality could weigh on the multiple. Execution on inventory and manufacturing reliability remains a watch item, as it underpins both fulfillment and margin performance.

Analyst Opinions

Recent six-month views are predominantly bullish, with a clear majority of Buy ratings versus Hold; notable Buy reiterations came from TD Cowen, Truist Financial, Ladenburg Thalmann, H.C. Wainwright, and other institutions, while BTIG maintained a Hold stance. TD Cowen emphasized the constructive impact of demand trends and burn-care contract visibility, reinforcing confidence in double-digit revenue growth this year. Truist Financial highlighted the balance of high-growth cartilage therapy and improving profitability metrics, while Ladenburg Thalmann pointed to ongoing procedure expansion and a multi-year runway. H.C. Wainwright underscored the strength of the cartilage franchise and the company’s balance sheet as supports for continued investment and execution. The majority view expects Vericel to deliver year-over-year revenue growth near the 18.19% consensus with seasonally soft earnings that do not detract from the full-year trajectory. Analysts generally see sustained high gross margins, constructive procedure pipelines into late spring and summer, and improving operating leverage as volumes normalize post-winter. In this framing, upside risk stems from better-than-expected cartilage procedure flow-through and incremental burn-care contributions, while downside risks are mainly tied to timing effects rather than demand degradation.